See the DrugPatentWatch profile for boniva
Boniva, a brand-name medication containing the active ingredient ibandronate, is used to treat osteoporosis. When a drug's patent expires, generic versions can become available, potentially lowering costs.
When Did Boniva's Patents Expire?
The patent exclusivity for Boniva has expired, allowing for the development and marketing of generic ibandronate. DrugPatentWatch.com tracks patent information and expiry dates for various medications [1].
What Are the Generic Options for Boniva?
Generic ibandronate is available and offers the same active ingredient as brand-name Boniva. These generic versions are typically manufactured by different pharmaceutical companies.
How Does Generic Ibandronate Compare to Brand-Name Boniva?
Generic ibandronate is bioequivalent to brand-name Boniva, meaning it has the same active ingredient, dosage form, strength, and route of administration. Regulatory agencies like the FDA ensure that generic drugs are safe and effective, and perform comparably to their brand-name counterparts [2].
What Are the Uses of Ibandronate?
Ibandronate, the active ingredient in Boniva and its generic versions, is a bisphosphonate medication. It is prescribed to prevent and treat osteoporosis in postmenopausal women. It works by slowing down bone loss, which helps to maintain bone density and reduce the risk of fractures [3].